Abstract
A series of substituted oxopropanylindole hydrazone derivatives was synthesized and evaluated for anti-oxidant and anti-dyslipidemic activity. Of the 12 tested, 3 compounds (6c, 7b and 7d) showed good anti-oxidant activity, compound 6c attenuated LDL oxidation by 32%. The compounds 6c and 7d also showed good anti-dyslipidemic activity by reducing serum levels of total cholesterol (TC), phospholipids (PL) and triglycerides (TG). These two compounds were further evaluated for antiadipogenic and anti-hyperglycemic activity, where 6c showed 44% reduction in lipid accumulation and 20.5% and 24.3% reduction in blood glucose at 5h and 24h respectively, as compared to standard drug metformin. Thus, compounds 6c and 7d with balanced anti-oxidant and anti-dyslipidimic activities may be excellent candidates for lead optimization and drug development for the treatment of metabolic disorders.
Keywords: Hydrazone derivatives, Anti-oxidant, Anti-dyslipidemic, Atherosclerosis, Lipid, Anti-hyperglycemic.
Graphical Abstract
Current Topics in Medicinal Chemistry
Title:Lipid Lowering Oxopropanylindole Hydrazone Derivatives with Antioxidant and Anti-hyperglycemic Activity
Volume: 18 Issue: 26
Author(s): Kanika Varshney, Amit K. Gupta, Ravi Sonkar, Salil Varshney, Akanksha Mishra, Geetika Bhatia, Anil Gaikwad, Arvind Kumar Srivastava, Mridula Saxena, Sudha Jain*Anil K. Saxena*
Affiliation:
- Department of Chemistry, Lucknow University, Lucknow, 226007,India
- Medicinal & Process Chemistry Division, Central Drug Research Institute, Lucknow, 226031,India
Keywords: Hydrazone derivatives, Anti-oxidant, Anti-dyslipidemic, Atherosclerosis, Lipid, Anti-hyperglycemic.
Abstract: A series of substituted oxopropanylindole hydrazone derivatives was synthesized and evaluated for anti-oxidant and anti-dyslipidemic activity. Of the 12 tested, 3 compounds (6c, 7b and 7d) showed good anti-oxidant activity, compound 6c attenuated LDL oxidation by 32%. The compounds 6c and 7d also showed good anti-dyslipidemic activity by reducing serum levels of total cholesterol (TC), phospholipids (PL) and triglycerides (TG). These two compounds were further evaluated for antiadipogenic and anti-hyperglycemic activity, where 6c showed 44% reduction in lipid accumulation and 20.5% and 24.3% reduction in blood glucose at 5h and 24h respectively, as compared to standard drug metformin. Thus, compounds 6c and 7d with balanced anti-oxidant and anti-dyslipidimic activities may be excellent candidates for lead optimization and drug development for the treatment of metabolic disorders.
Export Options
About this article
Cite this article as:
Varshney Kanika , Gupta K. Amit , Sonkar Ravi , Varshney Salil , Mishra Akanksha, Bhatia Geetika , Gaikwad Anil , Srivastava Kumar Arvind , Saxena Mridula, Jain Sudha*, Saxena K. Anil *, Lipid Lowering Oxopropanylindole Hydrazone Derivatives with Antioxidant and Anti-hyperglycemic Activity, Current Topics in Medicinal Chemistry 2018; 18 (26) . https://dx.doi.org/10.2174/1568026619666181220112903
DOI https://dx.doi.org/10.2174/1568026619666181220112903 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cardioprotective Peptides from Marine Sources
Current Protein & Peptide Science Inflammation Markers in Essential Hypertension
Medicinal Chemistry Why and How We Should Treat Elderly Patients with Hypertension?
Current Vascular Pharmacology Novel Concepts in the Pathogenesis and Management of Pediatric Hypertension
Current Pediatric Reviews Pathophysiology of Idiopathic Atrial Fibrillation - Prognostic and Treatment Implications
Current Pharmaceutical Design Long Chain Omega-3 Polyunsaturated Fatty Acids in Pediatric Metabolic Syndrome
Mini-Reviews in Medicinal Chemistry Contemporary Management of Hypertension - How to Optimize Therapy
Cardiovascular & Hematological Disorders-Drug Targets Nutraceuticals for Metabolic Syndrome Management: From Laboratory to Benchside
Current Vascular Pharmacology Facing Up the ROS Labyrinth - Where To Go?
Current Vascular Pharmacology Obesity-Associated Hypertension in Childhood: A New Epidemic Problem
Current Hypertension Reviews Is There an Association between Periodontitis and Hypertension?
Current Cardiology Reviews Programmed Cell Death after Intracerebral Hemorrhage
Current Neuropharmacology Chronic Hyperuricemia, Uric Acid Deposit and Cardiovascular Risk
Current Pharmaceutical Design A Systematic Approach to Hypertensive Urgencies and Emergencies
Current Hypertension Reviews Pathophysiology and Treatment of Obesity Hypertension
Current Pharmaceutical Design Cyclooxygenase-2 Inhibitors: A Painful Lesson
Cardiovascular & Hematological Disorders-Drug Targets The Physiology and Pathophysiology of a Novel Angiotensin Receptor-binding Protein ATRAP/Agtrap
Current Pharmaceutical Design Hypertension, Prehypertension and Blood Pressure Related Diseases
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Prebiotic Carbohydrates for Therapeutics
Endocrine, Metabolic & Immune Disorders - Drug Targets Abnormal Insulin Signaling: Early Detection of Silent Coronary Artery Disease-Erectile Dysfunction?
Current Pharmaceutical Design